Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin

Uma Borate, Amitkumar Mehta, Vishnu Reddy, Michaela Tsai, Neil Josephson, Ian Schnadig

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Systemic mastocytosis is a myeloproliferative neoplasm with varying presentation that is caused by infiltration of neoplastic mast cells into extracutaneous tissues. Cytoreductive therapy is used to control organ dysfunction in aggressive systemic mastocytosis and is sometimes needed for control of severe refractory symptoms in patients with indolent disease. However, current standard cytoreductive agents are limited by their suboptimal degree and duration of response and associated significant toxicities, highlighting the need for novel treatments for systemic mastocytosis. Recent studies have identified CD30 as a therapeutic target in systemic mastocytosis, as CD30 is expressed on a majority of neoplastic mast cells. In this case series, the clinical outcomes of 4 patients with aggressive or indolent systemic mastocytosis treated with the anti-CD30 antibody-drug conjugate brentuximab vedotin are reported. Two patients showed evidence of a response to treatment with a reduction in disease burden, 1 of which has demonstrated a durable response with ongoing benefit for more than 3 years. Treatment with brentuximab vedotin was well-tolerated with side effects that were effectively managed by dose modifications. The results presented suggest that brentuximab vedotin is active in systemic mastocytosis and can induce durable responses with a manageable toxicity profile.

Original languageEnglish (US)
Pages (from-to)25-31
Number of pages7
JournalLeukemia Research
Volume44
DOIs
StatePublished - May 1 2016

Fingerprint

Systemic Mastocytosis
Mast Cells
Therapeutics
cAC10-vcMMAE
Anti-Idiotypic Antibodies

Keywords

  • Brentuximab vedotin
  • Clinical trial
  • Hematologic neoplasms
  • Immunoconjugates
  • Mast cells
  • Monomethyl auristatin E

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. / Borate, Uma; Mehta, Amitkumar; Reddy, Vishnu; Tsai, Michaela; Josephson, Neil; Schnadig, Ian.

In: Leukemia Research, Vol. 44, 01.05.2016, p. 25-31.

Research output: Contribution to journalArticle

Borate, Uma ; Mehta, Amitkumar ; Reddy, Vishnu ; Tsai, Michaela ; Josephson, Neil ; Schnadig, Ian. / Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. In: Leukemia Research. 2016 ; Vol. 44. pp. 25-31.
@article{69ce2367db274d7e8d2cba3962fd320e,
title = "Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin",
abstract = "Systemic mastocytosis is a myeloproliferative neoplasm with varying presentation that is caused by infiltration of neoplastic mast cells into extracutaneous tissues. Cytoreductive therapy is used to control organ dysfunction in aggressive systemic mastocytosis and is sometimes needed for control of severe refractory symptoms in patients with indolent disease. However, current standard cytoreductive agents are limited by their suboptimal degree and duration of response and associated significant toxicities, highlighting the need for novel treatments for systemic mastocytosis. Recent studies have identified CD30 as a therapeutic target in systemic mastocytosis, as CD30 is expressed on a majority of neoplastic mast cells. In this case series, the clinical outcomes of 4 patients with aggressive or indolent systemic mastocytosis treated with the anti-CD30 antibody-drug conjugate brentuximab vedotin are reported. Two patients showed evidence of a response to treatment with a reduction in disease burden, 1 of which has demonstrated a durable response with ongoing benefit for more than 3 years. Treatment with brentuximab vedotin was well-tolerated with side effects that were effectively managed by dose modifications. The results presented suggest that brentuximab vedotin is active in systemic mastocytosis and can induce durable responses with a manageable toxicity profile.",
keywords = "Brentuximab vedotin, Clinical trial, Hematologic neoplasms, Immunoconjugates, Mast cells, Monomethyl auristatin E",
author = "Uma Borate and Amitkumar Mehta and Vishnu Reddy and Michaela Tsai and Neil Josephson and Ian Schnadig",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.leukres.2016.02.010",
language = "English (US)",
volume = "44",
pages = "25--31",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin

AU - Borate, Uma

AU - Mehta, Amitkumar

AU - Reddy, Vishnu

AU - Tsai, Michaela

AU - Josephson, Neil

AU - Schnadig, Ian

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Systemic mastocytosis is a myeloproliferative neoplasm with varying presentation that is caused by infiltration of neoplastic mast cells into extracutaneous tissues. Cytoreductive therapy is used to control organ dysfunction in aggressive systemic mastocytosis and is sometimes needed for control of severe refractory symptoms in patients with indolent disease. However, current standard cytoreductive agents are limited by their suboptimal degree and duration of response and associated significant toxicities, highlighting the need for novel treatments for systemic mastocytosis. Recent studies have identified CD30 as a therapeutic target in systemic mastocytosis, as CD30 is expressed on a majority of neoplastic mast cells. In this case series, the clinical outcomes of 4 patients with aggressive or indolent systemic mastocytosis treated with the anti-CD30 antibody-drug conjugate brentuximab vedotin are reported. Two patients showed evidence of a response to treatment with a reduction in disease burden, 1 of which has demonstrated a durable response with ongoing benefit for more than 3 years. Treatment with brentuximab vedotin was well-tolerated with side effects that were effectively managed by dose modifications. The results presented suggest that brentuximab vedotin is active in systemic mastocytosis and can induce durable responses with a manageable toxicity profile.

AB - Systemic mastocytosis is a myeloproliferative neoplasm with varying presentation that is caused by infiltration of neoplastic mast cells into extracutaneous tissues. Cytoreductive therapy is used to control organ dysfunction in aggressive systemic mastocytosis and is sometimes needed for control of severe refractory symptoms in patients with indolent disease. However, current standard cytoreductive agents are limited by their suboptimal degree and duration of response and associated significant toxicities, highlighting the need for novel treatments for systemic mastocytosis. Recent studies have identified CD30 as a therapeutic target in systemic mastocytosis, as CD30 is expressed on a majority of neoplastic mast cells. In this case series, the clinical outcomes of 4 patients with aggressive or indolent systemic mastocytosis treated with the anti-CD30 antibody-drug conjugate brentuximab vedotin are reported. Two patients showed evidence of a response to treatment with a reduction in disease burden, 1 of which has demonstrated a durable response with ongoing benefit for more than 3 years. Treatment with brentuximab vedotin was well-tolerated with side effects that were effectively managed by dose modifications. The results presented suggest that brentuximab vedotin is active in systemic mastocytosis and can induce durable responses with a manageable toxicity profile.

KW - Brentuximab vedotin

KW - Clinical trial

KW - Hematologic neoplasms

KW - Immunoconjugates

KW - Mast cells

KW - Monomethyl auristatin E

UR - http://www.scopus.com/inward/record.url?scp=84961140832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961140832&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.02.010

DO - 10.1016/j.leukres.2016.02.010

M3 - Article

VL - 44

SP - 25

EP - 31

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -